Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Enanta Pharmaceutica (ENTA)

Enanta Pharmaceutica (ENTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Enanta Pharmaceuticals (ENTA) Q3 Earnings Surpass Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 371.43% and -4.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ENTA : 72.35 (+0.22%)
Enanta Pharmaceuticals: Fiscal 3Q Earnings Snapshot

WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Tuesday reported fiscal third-quarter earnings of $7 million.

ENTA : 72.35 (+0.22%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2019

--

ENTA : 72.35 (+0.22%)
Enanta's HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET(TM) (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naive HCV Patients with Compensated Cirrhosis

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced...

ENTA : 72.35 (+0.22%)
AbbVie's MAVIRET(TM) (glecaprevir/pibrentasvir) Approved by European Commission to Shorten Treatment Duration to Eight Weeks for Treatment-Naive Patients with Chronic Hepatitis C and Compensated Cirrhosis

- MAVIRET(TM) is now available as a shorter, 8-week, once-daily option for treatment-naive, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT)1, 2, 4, 5 and 6

ENTA : 72.35 (+0.22%)
ABBV : 66.41 (-0.23%)
Enanta Pharmaceuticals to Host Conference Call on August 6 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced...

ENTA : 72.35 (+0.22%)
Enanta Pharmaceuticals (ENTA) Upgraded to Strong Buy: Here's What You Should Know

Enanta Pharmaceuticals (ENTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ENTA : 72.35 (+0.22%)
Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus (HBV)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced...

ENTA : 72.35 (+0.22%)
AbbVie's MAVIRET(TM) now listed on the Nova Scotia and Manitoba formularies

AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company announced today that MAVIRET(TM) (glecaprevir/pibrentasvir tablets) is now listed on the Nova Scotia Formulary and...

ENTA : 72.35 (+0.22%)
ABBV : 66.41 (-0.23%)
AbbVie's MAVIRET(TM) now listed in New Brunswick

AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company announced today that MAVIRET(TM) (glecaprevir/pibrentasvir tablets) is now listed on the New Brunswick Drug Plans...

ENTA : 72.35 (+0.22%)
ABBV : 66.41 (-0.23%)
Enanta Pharmaceuticals to Present at Upcoming Investor Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today...

ENTA : 72.35 (+0.22%)
Enanta Pharmaceuticals (ENTA) Beats Q2 Earnings Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 322.22% and -1.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?...

ENTA : 72.35 (+0.22%)
Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot

WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Tuesday reported fiscal second-quarter earnings of $4.1 million.

ENTA : 72.35 (+0.22%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019

--Data from Phase 2a RSV program anticipated mid-2019 and Phase 2a NASH program by the end of third quarter of calendar 2019

ENTA : 72.35 (+0.22%)
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ENTA : 72.35 (+0.22%)
Enanta Pharmaceu Rises 7.08% on Heavy Volume: Watch For Potential Pullback

Enanta Pharmaceu (NASDAQ:ENTA) traded in a range yesterday that spanned from a low of $88.40 to a high of $90.60. Yesterday, the shares gained 7.1%, which took the trading range above the 3-day high...

ENTA : 72.35 (+0.22%)
Enanta Pharmaceuticals to Host Conference Call on May 7th at 4:30 pm ET to Discuss Its Financial Results for Its Fiscal Second Quarter Ended March 31, 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today...

ENTA : 72.35 (+0.22%)
Enanta Pharmaceu Falls 2.58% on Heavy Volume: Watch For Potential Rebound

Enanta Pharmaceu (NASDAQ:ENTA) traded in a range yesterday that spanned from a low of $89.76 to a high of $92.17. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of...

ENTA : 72.35 (+0.22%)
Enanta Pharmaceuticals Presents New Preclinical Data on Compounds Targeting Hepatitis B Virus and Non-Alcoholic Steatohepatitis at The International Liver Congress(TM) 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced...

ENTA : 72.35 (+0.22%)
AbbVie's MAVIRET(TM) now reimbursed in Quebec

AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company announced today that MAVIRET(TM) (glecaprevir/pibrentasvir tablets) is now listed as a medication covered under Quebec's...

ENTA : 72.35 (+0.22%)
ABBV : 66.41 (-0.23%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
AIZ -1.07 , WELL -0.87 , SBAC -0.79 , CCI -0.35 , SO -0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar